TRCT
STAB

Tower Research Capital (TRC)’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,967
Closed -$2K – 6759
2022
Q4 		$2K Sell
29,967
-979
-3% -$124 ﹤0.01% 5521
2022
Q3 		$4K Buy
30,946
+7,125
+30% +$1.5K ﹤0.01% 5344
2022
Q2 		$7K Buy
+23,821
New +$6.16K ﹤0.01% 4872
2021
Q4 		– Sell
-13,891
Closed -$32K – 6869
2021
Q3 		$32K Buy
+13,891
New +$52.6K ﹤0.01% 3336
2020
Q3 		– Sell
-142
Closed – – 5225
2020
Q2 		$0 Buy
+142
New +$256 ﹤0.01% 5093
2016
Q4 		– Sell
-599
Closed -$1K – 4568
2016
Q3 		$1K Buy
+599
New +$1.32K ﹤0.01% 3419
2016
Q2 		– Sell
-1,114
Closed -$3K – 5170
2016
Q1 		$3K Buy
1,114
+1,014
+1,014% +$3.41K ﹤0.01% 3197
2015
Q4 		$0 Buy
+100
New +$403 ﹤0.01% 5234
2015
Q2 		– Sell
-467
Closed -$1K – 5218
2015
Q1 		$1K Buy
+467
New +$1.92K ﹤0.01% 4186
2013
Q4 		– Sell
-255
Closed -$8K – 5032
2013
Q3 		$8K Buy
+255
New +$8.44K ﹤0.01% 3382

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Tower Research Capital (TRC)'s STAB Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 29,967 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in STAB in Q3 2013 and held it in 10 quarters. The position peaked at $32K in Q3 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • Tower Research Capital (TRC) reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 29,967 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in Statera Biopharma, Inc. Common Stock in Q3 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Statera Biopharma, Inc. Common Stock position peaked at $32K in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.